<DOC>
	<DOC>NCT02414633</DOC>
	<brief_summary>A special investigation (post marketing observational study (PMOS)/non-mandatory) of HUMIRAÂ® will be performed for correlation between baseline and follow-up by clinical observation 24 weeks (planned visit time; before the start of treatment, and at 4, 12, 16, and 24 weeks, 4 data collection points) in Japanese psoriatic arthritis patients who are engaged in paid work.</brief_summary>
	<brief_title>Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment (WPAI))</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Paid workers (including parttime) with Psoriatic Arthritis, who have never administered adalimumab, and are diagnosed by ClASsification of Psoriatic ARthritis (CASPAR) criteria Subjects showing decreased basic activities of daily life such as hospitalization and bedridden Subjects with contraindications to adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
</DOC>